On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...